eCommons@AKU
Department of Medicine

Department of Medicine

May 2012

What is the role of free radical scavengers in acute
stroke?
Muhammad Faisal Wadiwala
Aga Khan University

Ambreen Sonawalla
Aga Khan University

Ayeesha Kamran Kamal
Agha Khan University, ayeesha.kamal@aku.edu

Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Neurology Commons
Recommended Citation
Wadiwala, M. F., Sonawalla, A., Kamal, A. (2012). What is the role of free radical scavengers in acute stroke?. JPMA. The Journal of the
Pakistan Medical Association, 62(5), 512-513.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/372

Evidence Based Medicine
What is the role of free radical scavengers in acute stroke?
Muhammad Faisal Wadiwala,1 Ambreen Sonawalla,2 Ayeesha Kamran Kamal3
Stroke Service and Vascular Fellowship Program, International Cerebrovascular Translational Clinical Research Training Program
(Fogarty International Center and National Institute of Neurologic Disorders and Stroke),1,3 Medical College,1 Aga Khan University, Karachi, Pakistan.
Corresponding Author: Ayeesha Kamran Kamal. Email: ayeesha.kamal@aku.edu

Effects of Edaravone, a Free Radical Scavenger, on
Serum Levels of Inflammatory Biomarkers in Acute Brain
Infarction.

Why is this study important and noteworthy?
Stroke may lead to functional disability. Much of this
tissue injury is a result of the release of free radicals, which
directly damage cells and also initiate other reactions which
lead to cerebral oedema. Free radicals, through
lipoperoxidation, cause increases in inflammatory cells and
mediators, and matrix metalloproteinases (MMP) in the
brain which leads to disruption of the blood-brain-barrier,
increase in vascular endothelial permeability and vasogenic
brain oedema.
Edaravone, a free radical scavenger, has been shown
to reduce the free radicals which are produced during
reperfusion in ischaemic cerebral injury, and inhibit
expression of MMP-9 in ischaemic brain models. However,
its effects on serum levels of inflammatory biomarkers have
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not been sufficiently studied.
This study was a prospective observational study,
aimed at investigating the effects of Edaravone treatment on
serum levels of inflammatory biomarkers, in patients with
acute cerebral infarction.

Who were the participants?
This study was a prospective observational study,
conducted in Japan, enrolling 69 patients (39 men and 30
women) who were admitted to the hospital within 12 to 36
hours of suffering an acute brain infarction, between April
2007 and September 2008. Edaravone was administered to
all the patients who had come within 12-24 hours of onset
of symptoms, whereas those admitted after 24-36 hours of
symptoms served as the control group.
This study excluded patients below 18 years, or
those with contraindications to edaravone treatment such as
serious kidney dysfunction, liver disorder, or
hypersensitivity to ingredients in edaravone. Patients with
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recurrent cerebral infarction (<6 months between episodes),
or previous history of heart disease such as heart failure or
ischaemic heart disease, were also excluded, as were those
with a disability having a modified Rankin scale (mRS)
score >2 before onset or those who required surgical or
endovascular interventions during hospitalization. Patients
with infections, inflammatory diseases, haematologic
disorders, malignancy requiring treatment, or pregnancy
were also excluded.

significantly suppressed circulating serum levels of MMP9. However, since in humans, the contribution of brain
tissue to the circulating levels of MMP-9 within 14 days
after onset of a stroke is unknown, these findings should not
be taken to reflect the effects of edaravone on ischaemic
brain per se. Edaravone did not significantly affect serum
levels of any other inflammatory biomarker. Further,
edaravone did not significantly affect functional outcomes
in patients.

What was the intervention and what were the
measurements?

How does this impact our clinical practice?

Patients who were admitted 12-24 hours after onset
of symptoms were administered 30 mg of edaravone diluted
in 100 mL of saline, every 12 hours for the next 14 days.
The edaravone was administered intravenously via dripinfusion over a 30 minute period.
Diagnosis of acute cerebral infarction was made by
neurologic examination and computed head tomography
and/or MRI. Serial blood samples were obtained from the
patients at admission, at 48 hours, 7 days and 14 days after
onset of symptoms and tested using ELISA for high-sensitivity
C-reactive protein (hs-CRP), Interleukins IL-6, IL-10, IL-18,
tumour necrosis factor (TNF)-α, MMP-2 and MMP-9.

What was the outcome?
Over the 14 days, there was no significant change in
MMP-9 levels in the edaravone group (p=0.564) whereas in
the control group MMP-9 levels increased from 3.857 to
4.538 ng/mL (p=0.027).
Unpaired t tests for other serum biomarkers showed
no significant differences between the two groups over the
observation period. There was also no significant difference
seen in the NIHSS score at 14 days, in the mRS score at 3
months, after onset of symptoms, or in the duration of
hospitalization.

This study does not conclusively demonstrate that
the suppression of circulating MMP-9 levels by edaravone
correlates with improved outcomes in relation to stroke
pathophysiology. However, the use of edaravone may help
combat the neurotoxicity following tPA-based
revascularization, since tPA is known to cause neurotoxicity
by many pathways, including increasing MMP-9 levels.
However, further studies need to be done to confirm this
beneficial effect. We should stay tuned for the effects of
edaravone which appear exciting in these 'preclinical
studies".
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